EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Omega‐3 and aspirin in the nonsurgical treatment of grade C periodontitis: A randomized clinical trial

Cássia F Araujo iD, Naira M R B Andere iD, Nidia C Castro Dos Santos iD, Laís F F Ferraz iD, Manuela M V Miguel iD, Ingrid F Mathias-Santamaria iD, Mabelle F Monteiro iD, Luciana M Shaddox iD, Renato C V Casarin iD, Mauro P Santamaria iD

Journal of Periodontology · 2025

DOI: 10.1002/jper.24-0322 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Periodontology, 2025. Verfasst von Cássia F Araujo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnosis and Surgery, Division of Periodontology, Institute of Science and Technology, São Paulo State University, São José dos Campos…. Hauptthemen laut MEDLINE: Aspirin, Periodontitis, Fatty Acids, Omega-3, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: São Paulo Research Foundation, Fundação de Amparo à Pesquisa do Estado de São Paulo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The use of omega‐3 (Ω‐3) polyunsaturated fatty acids and acetylsalicylic acid (ASA, aspirin) has shown better clinical outcomes in the treatment of periodontitis compared to nonsurgical periodontal therapy (NSPT) alone. This randomized clinical trial aimed to evaluate the use of 900 mg Ω‐3 and 100 mg ASA for 180 days as adjuncts to NSPT for generalized stage III–IV grade C periodontitis (GCP).

Methods

Patients underwent subgingival debridement (SD) associated with Ω‐3+ASA or cellulose placebo and received monthly prophylaxis. Clinical and immunological parameters were compared at baseline, 3, and 6 months after treatment. The daily dose of Ω‐3 consisted of 540 mg eicosapentaenoic acid (EPA) and 360 mg docosahexaenoic acid (DHA).

Results

Thirty‐eight patients, 12 males (7 in the SD+Ω‐3+AAS group and 5 in the SD+Placebo group; p > 0.05), with a mean age of 32.84 ± 5.47 and 30.42 ± 5.79 years, respectively ( p > 0.05), were included. Both groups showed significant improvements ( p < 0.05) in all full‐mouth parameters. Reductions in the number of pockets, mean probing depth (PD), and clinical attachment level of moderate and deep sites, as well as the number and percentage of residual pockets, were observed (intragroup p < 0.05; intergroup p > 0.05). However, residual pockets' mean PD decrease ( p < 0.05) was only observed at 6 months in the SD+Ω‐3+ASA group. The concentration of interleukin (IL)‐1β from moderate and deep pockets decreased ( p < 0.05) in both groups. The matrix metalloproteinase (MMP)‐9 to tissue metalloproteinase inhibitor (TIMP)‐1 ratio in the SD+Placebo group at 3 months revealed a proinflammatory profile in moderate (intergroup p = 0.006) and deep pockets (intergroup p < 0.001).

Conclusion

Ω‐3+ASA therapy did not add clinical benefits to the NSPT for generalized stage III–IV GCP, although some immunomodulatory benefits could be observed. Plain Language Summary The use of omega‐3 (Ω‐3) and aspirin (ASA) along with subgingival debridement (SD) for root decontamination of periodontal pockets has shown better results in the nonsurgical treatment of gum disease and bone loss compared to SD alone. This investigation aimed to evaluate the use of 900 mg Ω‐3 and 100 mg ASA for 180 days as adjuncts to the treatment of patients with gum disease and rapid bone loss rate. Thirty‐eight patients underwent SD associated with Ω‐3+ASA or placebo. Clinical and immunological parameters were evaluated at the beginning of the study and 3 and 6 months after. Both groups showed significant improvements. A significant reduction in the number of sites with diseased pockets was observed. The number of residual diseased sites was also significantly reduced, without differences between the groups. However, a significant decrease in the pocket size of the diseased sites was only observed at 6 months in the group that received Ω‐3+ASA. The concentration of interleukin (IL)‐1β (a protein present in the inflammatory process) from diseased sites significantly decreased in both groups. We concluded that the proposed therapy did not add any significant clinical benefits for patients with gum disease and rapid bone loss rate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AspirinPeriodontitisFatty Acids, Omega-3Anti-Inflammatory Agents, Non-SteroidalHumansMaleFemaleAdultPeriodontal DebridementEicosapentaenoic AcidTreatment OutcomeInterleukin-1betaPeriodontal PocketDocosahexaenoic AcidsPeriodontal IndexPeriodontal Attachment LossFollow-Up StudiesDouble-Blind MethodPlacebosCombined Modality TherapyDental Scaling

Stichwörter der Autor:innen

aspirinimmunomodulationinflammationomega‐3 fatty acidsperiodontal debridementperiodontitis

Substanzen

AspirinEicosapentaenoic AcidFatty Acids, Omega-3Anti-Inflammatory Agents, Non-SteroidalInterleukin-1betaDocosahexaenoic AcidsPlacebos

Autor:innen und Institutionen

  • Department of Diagnosis and Surgery, Division of Periodontology, Institute of Science and Technology, São Paulo State University, São José dos Campos, São Paulo, Brazil.
  • Division of Dentistry, Faculdade Santo Antônio, Caçapava, São Paulo, Brazil.
  • Dental Research Division, Guarulhos University, Guarulhos, São Paulo, Brazil.
  • Department of Oral Health Practice, College of Dentistry, University of Kentucky, Lexington, Kentucky, USA.
  • Department of Periodontics and Prosthodontics, Division of Periodontics, Piracicaba Dental School, University of Campinas, Piracicaba, São Paulo, Brazil.

ORCID-Profile: Cássia F Araujo, Naira M R B Andere, Nidia C Castro Dos Santos, Laís F F Ferraz, Manuela M V Miguel, Ingrid F Mathias-Santamaria, Mabelle F Monteiro, Luciana M Shaddox, Renato C V Casarin, Mauro P Santamaria

Förderung

  • São Paulo Research Foundation
  • Fundação de Amparo à Pesquisa do Estado de São Paulo

Zitieren

APA

Araujo, C. F., Andere, N. M. R. B., Castro Dos Santos, N. C., Ferraz, L. F. F., Miguel, M. M. V., Mathias-Santamaria, I. F., Monteiro, M. F., Shaddox, L. M., Casarin, R. C. V., & Santamaria, M. P. (2025). Omega‐3 and aspirin in the nonsurgical treatment of grade C periodontitis: A randomized clinical trial. Journal of Periodontology. https://doi.org/10.1002/jper.24-0322

Vancouver

Araujo CF, Andere NMRB, Castro Dos Santos NC, Ferraz LFF, Miguel MMV, Mathias-Santamaria IF, et al. Omega‐3 and aspirin in the nonsurgical treatment of grade C periodontitis: A randomized clinical trial. Journal of Periodontology. 2025. doi:10.1002/jper.24-0322

BibTeX
@article{Araujo2025,
  author = {Araujo, Cássia F and Andere, Naira M R B and Castro Dos Santos, Nidia C and Ferraz, Laís F F and Miguel, Manuela M V and Mathias-Santamaria, Ingrid F and Monteiro, Mabelle F and Shaddox, Luciana M and Casarin, Renato C V and Santamaria, Mauro P},
  title = {Omega‐3 and aspirin in the nonsurgical treatment of grade C periodontitis: A randomized clinical trial},
  journal = {Journal of Periodontology},
  year = {2025},
  doi = {10.1002/jper.24-0322}
}
Kostenlos starten →